My Star
An Asher Barreras original composition. Played at the Arts in Medicine concert at UNM Hospital, Albuquerque, NM, 12/12/12. Steve Seifert, Tenor Sax, Sam Negri, Keyboard, Chad Scheer, Bass, Asher Barreras, Drums.From:JazzizallViews:0 0ratingsTime:05:13More inMusic
Excerpt from:
Obesity Week - Big Love
uOttawa Medicine Year II - Obesity Week Project Jonathan Blankenstein Gregory Drozdzal Taylor Ferrier Vashti King Nischal Ranganath Brianna Ryman Alyssa Smith Michael WangFrom:flyingduckieViews:6 0ratingsTime:03:13More inEducation
See original here:
On Green Dolphin Street (Cover)
Our cover of On Green Dolphin Street, at the "Arts in Medicine" concert at UNM Hospital, Albuquerque, NM, 12/12/12. Steve Seifert, Tenor Sax, Sam Negri, Keyboard, Chad Scheer, Bass, and Asher Barreras, DrumsFrom:JazzizallViews:1 0ratingsTime:04:06More inMusic
Here is the original post:
Myofascial Release for Rectus Femoris and hamstrings
John Gibbons a registered Sports Osteopath and lecturer in sports medicine is demonstrating Active release techniques (ART) or Soft tissue Release (STR) for the Rectus Femoris and Iliotibial band (IT Band). If you are interested in attending one of John #39;s Certified Physical therapy CPD Courses at the iconic venue of Oxford University look on: http://www.johngibbonsbodymaster.co.ukFrom:John GibbonsViews:4 0ratingsTime:05:03More inEducation
Link:
Myofascial Release for Rectus Femoris and hamstrings - Video
The American College of Preventive Medicine (ACPM) has announced a partnership with the Ardmore Institute of Health to form an expert steering committee to develop a framework, based on established physician competencies, which would facilitate and advance the adoption of lifestyle medicine into clinical practice.
Washington, DC (PRWEB) December 12, 2012
With the enormous potential effects of health behavior change on mortality, morbidity, and health care costs, the motivation for embracing the concept of lifestyle medicine is clear, explained Miriam Alexander, MD, MPH, FACPM, President of ACPM. We have a consensus set of competencies; now we need a blueprint for developing curricula, practice tools, and advocacy materials, all of which will support physicians in implementing lifestyle medicine best practices.
The panel, which will convene February 20, 2013 at ACPMs Preventive Medicine 2013 conference in Scottsdale, AZ, is charged with identifying a pathway for helping physicians adopt lifestyle medicine in their clinical practice. Panel members, mostly recognized leaders in preventive medicine, bring expertise and perspectives from various workplace settings and will contribute important stakeholder perspectives, such as clinical practice, academic medicine, public health, health promotion research, health plans and insurance providers, professional medical societies, and corporate employers. The panels efforts will focus on the physician competencies for prescribing lifestyle medicine previously published in JAMA (Lianov L; Johnson M. Physician competencies for prescribing lifestyle medicine. JAMA. 2010; 304(2):202-3). Liana Lianov, MD, MPH, FACPM, ACPMs Public Health and General Preventive Medicine Regent, President of the American College of Lifestyle Medicine, and chair of ACPMs Lifestyle Medicine Task Force, has been tapped to lead the panel. This group of thought leaders will explore multiple aspects of lifestyle medicine practice and policy and deliver a plan for integrating lifestyle medicine into clinical practice, health care delivery systems, and payment/reimbursement models, says Dr. Lianov. The plan will identify ways to empower key stakeholders, from primary care physicians in the trenches to health care delivery systems struggling to adapt to reforms that reward improved outcomes for populations, with proven approaches to reducing risk and preventing and reversing disease burden. Its an exciting undertaking which Im honored to lead.
Funding for the initiative was provided by the Ardmore Institute of Health. We are proud to support this effort which engages the brightest minds in the field to advance the cause of behavioral change, risk reduction, and the prevention and treatment of disease, noted Sid Lloyd, President and CEO of the Ardmore Health Institute. This is an important and timely endeavor, and one that could have significant and lasting impact on our nations healthcare system.
About the American College of Preventive Medicine
Founded in 1954, the American College of Preventive Medicine (ACPM) is a U.S.-based physician organization focused on practice, research, publication, and teaching of evidence-based preventive medicine. As the umbrella society for the specialty of Preventive Medicine and physicians dedicated to prevention, ACPM seeks to improve the health of individuals and populations through evidence-based health promotion, disease prevention, and systems-based approaches to improving health and health care. For more information, visit http://www.acpm.org.
About Ardmore Institute of Health
Ardmore Institute of Health (AIH) is a public charity on a mission to improve the health and vitality of people to live more meaningful lives. Headquartered in Ardmore, OK, AIH makes the journey toward better health as simple, fun and exciting as possible in each product it develops, such as its New York Times best-selling, "The Full Plate Diet."
# # #
View post:
When I was a sophomore in college, my mother unfortunately lost her very short battle with pancreatic cancer, an experience that changed my life forever. During that time I witnessed firsthand the devastating effects caused by the administration of toxic, non-specific treatments which ultimately failed to stop the spread of the cancer, and instead only made my mother extremely sick. Her death, at the young age of 44, profoundly influenced my feelings towards medicine and altered my career path. As a result, I became driven to discover better drugs for treating cancer, with a focus to specifically target diseased cells while leaving healthy tissues unharmed.Thankfully, my passion for developing smarter cancer drugs is shared by many others, and it has been exciting to see the progress made over the years in developing treatments that can be characterized as "personalized medicines". A commonly cited example that demonstrates the impact of personalized medicine in cancer is the successful development of the breast cancer drug, Herceptin(R), which specifically targets aggressive HER2-positive breast cancer. Importantly, before this medication was developed, women with HER2-expressing breast cancer were less responsive to standard treatments. Now, however, treatment with Herceptin in combination with chemotherapy has amazingly been shown to reduce the recurrence rate of this type of cancer by 52 percent.Building on Biomarkers: Companion DiagnosticsA biomarker is a unique trait of a disease, such as genetic marker or overexpressed protein like HER2. Developing a medicine that targets a specific biomarker can have a positive effect on patient outcome, but this approach is only one part of the therapeutic equation. To truly fulfill the promise of personalized medicine, there must also be a tool available for identifying those patients bearing that biomarker. An agent of this type is called a companion diagnostic. The outcome of this type of test should enable the right drug to be administered, to the right person, at the right time. In this manner, a companion diagnostic helps to identify those patients that may benefit from a given targeted treatment while at the same time identifying patients that will likely not benefit from therapy. Related to the example above, such a test is available to determine if a patient has HER2-positive breast cancer, and it is performed before Herceptin is prescribed.Recently, due to the benefits realized from biomarker testing, interest in developing companion diagnostics has surged. The FDA is very supportive of the development of these patient-selective tests. In fact, one companion diagnostic was approved this year and two within the same month last year to accompany Pfizer's targeted drug for lung cancer, Xalkori(R), and Roche's personalized therapeutic for melanoma, Zelboraf(R). Importantly, Roche stated that it aims to have 60 percent of its drugs in development to be accompanied by some form of a companion test, an indication that, like the FDA, the pharmaceutical industry is also embracing the continued development of companion diagnostic agents.There are many reasons for the significant interest in this space that stem from the benefits of identifying patients with companion diagnostics. For example, in the area of cancer, where development of these agents is most advanced, significant delay of tumor growth and increased survival rates have been demonstrated in patients that were preselected using a companion diagnostic. Having the ability to determine whether a patient may or may not respond to a given treatment enables the selection of the best medicine for that individual, without wasting precious time with trial and error approaches.It is precisely this advantage that allows clinical trials to be conducted in a specific patient population, which can decrease the size and related cost of these studies. Lower costs may allow drug developers to use such savings to invest in additional areas of disease research. Furthermore, smaller clinical trial size means that studies can be conducted more quickly, which could accelerate the arrival of these treatments to the market and broaden access to patients. Collectively, these conserved resources translate into savings for the entire healthcare system, which is an important benefit as rising healthcare costs are a significant issue for our nation.It is worth noting that a recent paper published in the New England Journal of Medicine showed that the genetic characteristics of a tumor, such as biomarker expression, can and often do change over time. Thus, in contrast to conventional companion diagnostics that typically utilize tissue samples obtained through biopsy (especially those performed on archived tissue), additional benefits are found with the use of companion diagnostics that are based on whole-body imaging. Results obtained from non-invasive, real-time imaging methodology, therefore, provide the most up-to-date biomarker information possible to inform treatment decision making. But, regardless of the method employed, the impact of patient selection can be substantial.A New ApproachAt Endocyte, we have seen this patient-selective approach translate into positive clinical results. The technology we're developing consists of targeted therapeutics called small molecule drug conjugates, or SMDCs. Each of these novel compounds consists of a high affinity, cell-specific targeting molecule (the ligand) that is chemically linked to a potent chemotherapy drug. This yields a highly potent, yet selective therapeutic agent; but, this approach also allows us to easily create a companion diagnostic by simply replacing the chemotherapeutic drug in the SMDC construct with an imaging agent.Vintafolide is our most advanced SMDC in development. This therapeutic binds to the folate receptor, which is a confirmed biomarker expressed on many human cancers, including ovarian, lung, breast and colon. Vintafolide's companion diagnostic imaging agent (etarfolatide) is designed to identify cancer patients that have high levels of the folate receptor expression, which is the exact population of patients expected to respond to this drug.In a previous clinical trial in patients with platinum-resistant ovarian cancer, women identified as "FR-positive" by etarfolatide and then subsequently treated with vintafolide had significantly delayed tumor growth. Based on these unprecedented results, especially in a patient population that fails to adequately respond to any therapy, both etarfolatide and vintafolide are being considered for conditional approval in Europe. This could mean that patients would have access to these agents much sooner than expected. Overall, this exciting opportunity would never have been possible if our companion diagnostic agent was not used to select the right patient population to treat with vintafolide in our clinical trials.A Promising FutureBecause of the numerous benefits companion diagnostics hold for patients, physicians, drug developers and our healthcare system, their continued development and use will only increase in the future. Regulatory agencies worldwide are also embracing this approach, and they continue to encourage drug developers to pursue this path for the treatment of all types of diseases. As the number of companion diagnostics in development continues to grow, we are moving closer each day to truly fulfilling the promise of personalized medicine. Follow Scientific American on Twitter @SciAm and @SciamBlogs.Visit ScientificAmerican.com for the latest in science, health and technology news. 2012 ScientificAmerican.com. All rights reserved.
Read the original post:
Advancing the Promise of Personalized Medicine: Companion Diagnostics
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--
MEDNAX, Inc., (MD) today announced the acquisition of a maternal-fetal medicine physician practice based in Lithia Springs, Georgia. The practice will become part of MEDNAXs Pediatrix Medical Group division.
Raj K. Bansal, M.D., P.C., was established in 2002 and is a private practice that consists of one maternal-fetal medicine physician and eight clinical and administrative support staff who provide care to expectant mothers, including the management of high-risk and complicated pregnancies, throughout the Atlanta area. The practice provides maternal-fetal services at five area hospitals, including Wellstar Cobb Hospital, Wellstar Douglas Hospital, Wellstar Kennestone Hospital, Piedmont Hospital and Atlanta Medical Center.
Given the changing and uncertain healthcare environment, we felt that now is the ideal time to partner with a leading national medical group practice, said Raj Bansal, M.D., who will serve as medical director for the practice. We look forward to experiencing the support of a national administrative infrastructure that allows us the opportunity to spend more time caring for our patients.
Dr. Bansal will now be part of MEDNAX's Pediatrix Medical Group, a national medical group consisting of the nation's leading neonatal, maternal-fetal medicine, pediatric cardiology, and other pediatric specialty physicians.
The practice was acquired for cash and the transaction is expected to be immediately accretive to its earnings. No additional terms of the transaction were disclosed.
With this acquisition, 13 physician group practices have become part of MEDNAX in 2012, seven as part of Pediatrix Medical Group, and six as part of American Anesthesiology.
ABOUT MEDNAX
MEDNAX, Inc. is a national medical group that comprises the nation's leading provider of neonatal, maternal-fetal and pediatric physician subspecialty services as well as anesthesia services. Physicians and advanced practitioners practicing as part of MEDNAX are reshaping the delivery of care within their specialties and subspecialties, using evidence-based tools, continuous quality initiatives and clinical research to enhance patient outcomes and provide high-quality, cost-effective care. Pediatrix Medical Group, a unit of MEDNAX, was founded in 1979 and now includes neonatal physicians who provide services at more than 300 neonatal intensive care units, who collaborate with affiliated maternal-fetal medicine, pediatric cardiology and pediatric critical care physician subspecialists to provide a clinical care continuum. Pediatrix is also the nation's largest provider of newborn hearing screens. In 2007, MEDNAX expanded into anesthesia services. Today, American Anesthesiology includes more than 1,250 anesthesiologists and advanced practitioners who provide anesthesia care to patients in connection with surgical and other procedures as well as pain management. MEDNAX, through its affiliated professional corporations, employs more than 1,925 physicians in 34 states and Puerto Rico. Additional information is available at http://www.mednax.com.
Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as believe, hope, may, anticipate, should, intend, plan, will, expect, estimate, project, positioned, strategy and similar expressions, and are based on assumptions and assessments made by MEDNAXs management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and MEDNAX undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in MEDNAXs most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled Risk Factors, as well MEDNAXs current reports on Form 8-K, filed with the Securities and Exchange Commission.
Go here to read the rest:
MEDNAX Announces Acquisition of Maternal-Fetal Medicine Practice in Georgia
NEW YORK, Dec. 12, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Nuclear Medicine Industry http://www.reportlinker.com/p080450/Global-Nuclear-Medicine-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging
This report analyzes the worldwide markets for Nuclear Medicine in US$ Million by the following Product Segments: Gamma Cameras, and PET Scanners. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. A six-year historic analysis is also provided for these markets. The report profiles 43 companies including many key and niche players such as Digirad Corporation, GE Healthcare Plc, Phillips Healthcare, Inc., Positron Corporation, Siemens Medical Solutions USA, Inc., Toshiba Medical Systems Corporation, and Toshiba America Medical Systems, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations I-1 Disclaimers I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Product Definitions and Scope of Study I-3 Gamma Cameras I-3 PET Scanners I-4
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW AND OUTLOOK II-1 Market Snapshots II-1 Nuclear Medicine - An Introduction II-1 Market Witnesses Turbulent Times in Recent Past II-2 Isotope Supply Shock - A Major Factor for Market Decline II-2 Market Rebounds; Brighter Prospects Ahead II-2 Growth Drivers in a Nutshell II-3 Current and Future Analysis II-3 Emerging Markets to Drive Growth; US Still in Spotlight II-4 Susceptibility to Cardiac Disease, Brain Disorders and Cancers Influence Procedure Volumes II-4 Minimal Impact of Recession on the Medical Contrast Media Market II-4
2. TRENDS AND ISSUES II-5 Global Technetium Shortage Eased II-5 Market Shifts to Hybrid Imaging II-5 PET Eats its Way into Conventional Gamma Camera Market II-6 PET-MRI Emerging as a Promising Standard for Imaging Soft Tissue Contrast II-6 High Costs - A Major Threat for Market Growth II-6 Technology Innovations Promise Bright Prospects II-7 New Innovations in the Nuclear Medicine Device Market II-7 SPECT/CT Scanners Drive Nuclear Medicine Equipment Market in North America II-7 Global Nuclear Medicine Market - Historic Statistics II-8 Table 1: Global Gamma Cameras Market (2006): Installed Based in Units by Select Country - USA, Japan, Canada, and UK (includes corresponding Graph/Chart) II-8
Table 2: Global PET Scanners Market (2006): Installed Base in Units by Select Country - USA, Europe, Japan, Germany, Canada, UK, France, Italy, and Belgium (includes corresponding Graph/Chart) II-8
3. COMPETITIVE LANDSCAPE II-9 Competition Overview in Nuclear Medicine Market II-9 Table 3: Leading Players in the Global Gamma Camera Market (2010 & 2011): Percentage Breakdown of Value Sales for Philips Healthcare, Siemens Healthcare, GE Healthcare, and Others (includes corresponding Graph/Chart) II-9
Table 4: Leading Players in the Global PET Scanner Market (2010 & 2011): Percentage Breakdown of Value Sales for Siemens Healthcare, GE Healthcare, Philips Healthcare and Others (includes corresponding Graph/Chart) II-10 Leading Players in the Worldwide Nuclear Medicine Market: A Completive Analysis II-11
Visit link:
"For Your Entertainment" - Kuroshitsuji/Black Butler Grell-"lesque" Alternate Cut
Video Footage by Lily Oliver and LeRoy Menahan, sit-in guest: Robin A. For the "Cheeky Geeky Vaudeville", I did my Grell-"lesque". Apart from wardrobe malfunctions and the fact that I was VERY out of it and on energy drinks and cold medicine, I still enjoy this piece. It is far from my best, but I look forward to doing it again (without wardrobe malfunctions and with better costume pieces). I made the costume myself, and yes, I know I #39;m not wearing the right shoes: but being on cold medicine and wearing 4" heels was not a very good idea. I don #39;t own Adam Lambert #39;s song, "For Your Entertainment", nor do I own Kuroshitsuji/Black Butler or Grell. I just had fun acting as this character and dancing to this song :)From:RipleyRedrumViews:0 0ratingsTime:03:52More inEntertainment
Read the rest here:
"For Your Entertainment" - Kuroshitsuji/Black Butler Grell-"lesque" Alternate Cut - Video
NEC 13 Marlin Pie vs Happy Medicine crowd view
Marlin Pie vs Happy Medicine at NEC13From:BlackShinobi13Views:2 0ratingsTime:04:47More inGaming
See the article here:
Sobecki FinalProject
Final animation to "Warehouse Medicine"From:JYS9906Views:0 0ratingsTime:00:27More inPeople Blogs
Read more from the original source:
Southern California Dermatologist Dr. Tess Mauricio Look Your Best for the Holidays and Time Machine
America #39;s Favorite Dermatologist, Dr. Tess Mauricio, talks about her special Time Machine package of treatments, including Venus Freeze. Look your best for the holidays Dr. Tess is a world-renowned cosmetic dermatologist, physician trainer, researcher, and media personality. You #39;ve seen her in everything from Cosmo Magazine UK and San Diego Living to national shows like The Rachael Ray Show, America #39;s Next Top Model, and The Doctors. A graduate of Stanford University School of Medicine, she was the youngest woman president of the San Diego Society for Dermatologic Surgery, crowned Mrs. Philippines San Diego in 2011, and is a "FWN 100 Most Influential Women" awardee. Dr. Tess hosts her own talk show, RSVP, which airs Sundays at 7:40pm on GMA Pinoy TV. Scripps Ranch Dermatology Cosmetic Center, San Diego CA M Beauty by Dr. Tess now open in National City, Glendale, and Del Mar/Solana Beach! http://www.mbeautyclinic.com http://www.tessmd.com rsvptalkshow.comFrom:awPVTViews:0 0ratingsTime:03:47More inScience Technology
Read the rest here:
Mindfulness with Jon Kabat-Zinn Video
Jon Kabat-Zinn, leading expert on mindfulness practices and the pivotal figure in bringing Buddhist meditation to Western medicine, discusses the essence and foundational principles of mindfulness, inspiring all of us to embrace the "full catastrophe" of life. For the full video go to: http://www.psychotherapy.netFrom:PsychotherapyNetViews:3 0ratingsTime:03:09More inEducation
Read more:
Spidermonkey- Legion Legacy (orignal)
instrumental by dannson beats lyrics-angels demonic services iconic the dresses you down the precarious novelist, raggae a serenade of novice listings the stress an adequat lesson time table the dominoes incredible devices solvable the caress an irreversable dominatable, confessions they stole a base, should have picked them off should #39;ve threw them out, back to the batters cage realligned defense sensual masculades, and blade trades the curious fades, I have a chance to score, offensive lectures the simpliest the sectors, * she gazed upon his sore eyes with such adequet measure* the lines tell the level off and the temperment sees honesty with blocks of softness, the tathered envelope the letter an extra scape goat I made a mistake but the electorial votes won #39;t decide my elopement, just the strange encounters to stream a life boat, *this isn #39;t music it #39;s medicine, these aren #39;t lyrics this is a coping skill, to deal with my fury, to balance out the awkward telecom, and fuse spiritual energy to it #39;s super color* got to blemish my sore ego with a sensibility and reanaylze this corrupted preliminary, like I said they stole a base, but the pitcher only needs one more out the team needs to get back on offense, cheese pizza gives me speed, holy graceful stream the accosted stems smoke leaves strendous sorrow a marketer to the way of things, I #39;ve marveled over every standard high cost the price a sonar agile corteous the steamer rolls, trying to configure this color of cubes ...From:antscribesViews:0 0ratingsTime:03:45More inEntertainment
Excerpt from:
New Medicine Live
Feb 2012. In Washington State. Other bands that played were Stone Sour, Avenged Sevenfold and Hollywood Undead. :)From:AndreaSt55Views:0 0ratingsTime:00:21More inMusic
Read the original post:
The Streets Are Talking
My essay "The Streets Are Talking: Chronicles Of A Brown Flaneur" is what I read at ANDPVA #39;s members show. A packed crowd of 30 laughed, cheered, clapped, and whistled as I read. This essay is published in "Yellow Medicine Review" Fall 2012. It is about me walking in 4 cities: Berlin, Guangzhou, Toronto, Quito. SUBSCRIBE to blackcoffeepoet.com for FREE: blackcoffeepoet.com SUBSCRIBE to the Black Coffee Poet YOUTUBE Channel FREE!!!From:BlackCoffeePoetViews:1 0ratingsTime:14:39More inTravel Events
Original post:
One positive facet of Obamacare is the rebuilding of our primary care system. Unfortunately, congressional forces are aligning that will obstruct replacing the back bone of our health care system. Even more surprising, the proposed congressional actions are bipartisan in nature and bipartisan work tends to pass into law. How is this happening?
Go here to read the rest:
ATLANTA — Carl H. June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania and the director of Translational Research in Penn’s Abramson Cancer Center, will be honored as a recipient of the American Society of Hematology’s 2012 Ernest Beutler Lecture and Prize today at the ...
Excerpt from:
Four second period goals helped last-place Medicine Chest topple top-ranked Kilrich 6-5 in oldtimer hockey action last night.
Here is the original post:
BURLINGTON, Mass., Dec. 11, 2012 (GLOBE NEWSWIRE) -- Bridgeline Digital, Inc. (BLIN), The Digital Engagement Company(TM), today announced the launch of a new website for The Society of General Internal Medicine (SGIM) at SGIM.org. SGIM joins a growing number of healthcare organizations including American Dental Association, the American Academy of Dermatology, and the Maryland Hospital Association to select Bridgeline Digital's iAPPS platform to power its next generation websites.
Bridgeline Digital redeveloped SGIM's main website and consolidated and enhanced two microsites run by SGIM affiliate groups: the Association of Chiefs in General Internal Medicine (ACLGIM), and SGIM's Journal of General Internal Medicine (JGIM). The SGIM main site and the new micro site for the ACLGIM are now live and the new microsite for the JGIM is in development and expected to launch in early 2013.
Bridgeline's development team added a dynamic Social Footer to SGIM's primary website which incorporates interaction and content from LinkedIn, Twitter, and Facebook that enables increased engagement and understanding of their website users. Bridgeline also added a comprehensive customization feature allowing SGIM to change microsite-based templates with ease to respond to changes in their marketing strategy.
SGIM's new website also features innovative functionality around internal search and data recovery in its Resource Library. Leveraging iAPPS' out-of-the-box integration with Perceptive Software Enterprise Search (formerly ISYS Search), the new site leverages search component catalogs natively within the iAPPS framework and indexes all media types, including content within PDF files vastly improving the ease and speed in which users can access relevant content.
"Bridgeline Digital was extremely innovative with their services," said Francine Jetton, Society of General Medicine's Director of Communications. "The Social Footer strengthens SGIM's presence and activity across social media outposts, which is a key component of our marketing strategy and critical for our business success going forward."
About The Society of General Internal Medicine
SGIM is a member-based international association of over 3,000 of the world's leading general internists, who are dedicated to improving access to care for vulnerable populations, eliminating health care disparities and enhancing medical education. The members of the Society advance the practice of medicine through their commitment to providing comprehensive, coordinated, and cost-effective care to adults, educating the next generation of outstanding physicians, and conducting cutting-edge research to improve quality of care and clinical outcomes of all patients.
About Bridgeline Digital
Bridgeline Digital (BLIN), The Digital Engagement Company(TM), enables its customers to maximize the performance of their mission critical websites, intranets, and online stores. Bridgeline's iAPPS(R) platform deeply integrates Web Content Management, eCommerce, eMarketing, and Web Analytics to help marketers deliver online experiences that attract, engage and convert their customers across all digital channels. Bridgeline provides end-to-end Digital Engagement solutions and boasts an award-winning team of interactive services professionals. Headquartered in Burlington, Mass., with nine additional locations throughout the U.S. and an Asia Pacific headquarters in Bangalore, India, Bridgeline has thousands of customers that range from middle market organizations to Fortune 1,000 companies. To learn more, please visit http://www.bridgelinedigital.com or call (800) 603-9936.
See the article here:
Society of General Internal Medicine Launches New Website on Bridgeline Digital's iAPPS Platform